Draft:Oxford BioDynamics

• Comment: One clear big problem is the overuse of Businesswire as a source Cinder painter (talk) 04:31, 17 June 2025 (UTC)

---

Oxford BioDynamics plc (OBD) is a UK-based biotechnology company that develops epigenetic biomarker tests for precision medicine. It was spun out from the University of Oxford in 2007 by Christian Hoyer Millar, Dr. Alexandre Akoulitchev and Dr. Aroul Ramadass. The company is headquartered in Oxford, with laboratories in the US and Malaysia. It listed on the London Stock Exchange’s AIM market in 2016, raising £20 million. OBD’s proprietary EpiSwitch platform profiles the 3D structure of the genome to identify biomarkers predictive of disease or therapy response.

History

Oxford BioDynamics won a Queen’s Award for Enterprise in 2019 and pivoted in 2020 toward diagnostic test development. In 2021, it opened a new 24,000 sq ft headquarters and lab in Oxford. During the COVID-19 pandemic, it launched EpiSwitch CST, a severity predictor. In 2022, it introduced EpiSwitch CiRT, a blood test predicting response to immune checkpoint inhibitors (ICI), with 85% accuracy. It received a PLA CPT code in 2022 and New York State CLEP approval in 2024. In 2023, the company launched EpiSwitch PSE, a prostate cancer test combining PSA and epigenetic markers, achieving 94% accuracy. In 2020, Dr Jon Burrows was appointed CEO to support US expansion efforts. He stepped down in December 2024 and was succeeded by Iain Ross as Executive Chairman.

Products and technology

Oxford BioDynamics’ products utilize its proprietary EpiSwitch platform to analyze the 3D genome structure for clinical applications. EpiSwitch CiRT is a blood-based companion diagnostic test used to predict patient response to immune checkpoint inhibitors in cancer treatment. It is offered in the US and UK and is currently being used in a real-world study (PROWES). EpiSwitch PSE, a prostate cancer screening test that combines epigenetic biomarkers with PSA measurement, received CPT code 0433U in the US and is being adopted in UK clinics. EpiSwitch CST, developed during the COVID-19 pandemic, aids in predicting disease severity. The EpiSwitch Explorer Array, developed in collaboration with Agilent, is intended for research use in genome-wide epigenetic profiling.

Partnerships

OBD has partnered with pharma firms including Pfizer, Roche, Biogen, and Mitsubishi Tanabe, and with hospitals like Mayo Clinic and MGH. In the US, it partnered with NEXT Molecular Analytics, and in the UK with Goodbody Clinic and The London Clinic. In 2023, Bupa UK began reimbursing CiRT. and in 2025 added the PSE test. OBD also leads a consortium shortlisted by the UK government to integrate CiRT into NHS trials.